HGH (Somatropin).
Recombinant human growth hormone — physician-supervised use only.
Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.
- ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
- ✓Patient-named prescription only — dispensed against a valid Rx.
- ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
- ✓Cold-chain shipping across EU/EEA — 2–5 working days.
About HGH (Somatropin).
Recombinant human growth hormone (rhGH, somatropin) holds Marketing Authorisations across the EU for paediatric and adult growth-hormone deficiency, Turner syndrome, chronic renal insufficiency in children, and a handful of other indications.
Magistral preparation of rhGH is reserved for cases where the licensed product is not available or not suitable, under physician supervision. rhGH carries genuine endocrine effects and requires careful monitoring of IGF-1, glucose and other parameters.
rhGH binds the GH receptor on hepatocytes (driving IGF-1 production), adipocytes (driving lipolysis), and other tissues. Most growth and anabolic effects are mediated by hepatic IGF-1.
Subcutaneous injection, typically once daily before sleep. Doses are highly individualised; physician monitors IGF-1 monthly during initiation.
Your physician sets the prescription. This is descriptive information, not a self-administration guide.
Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.
- INN / Name
- HGH (Somatropin)
- Form
- Lyophilised vial · subcutaneous injection
- Strength
- 36IU 3ml vial
- Manufacturing
- EU-GMP Annex 1 · Grade A/B
- Endotoxins
- European Pharmacopoeia 2.6.14 · LAL assay
- Identity & purity
- HPLC + MS · > 98%
- Cold chain
- Validated 2–8 °C, monitored end-to-end
- Regulatory basis
- Directive 2001/83/EC · Article 5(1)
2–5 working days
EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.
Magistral preparation
Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.
EU prescription recognition
Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.